Clinical trial · Observational
Added Value of PET/CT in Assessment of Hepatocellular Malignancy Post Radiofrequency Ablation
NCT06960031CI-TRIAL-00089938completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to assess the residual tumoral activity versus the well ablation of اepatocellular carcinoma (HCC) post radiofrequency ablation.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Malignancy | — | UNRESOLVED | — |
| PET/CT | — | UNRESOLVED | — |
| Radiofrequency Ablation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET/CT technique | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- PET/CT
- description
- Hybrid positron emission tomography (PET) and computed tomography (CT) images will be performed using Philips hybrid system equipped with a 16 MDCT scanner. The whole-body PET images from the skull vault down to the knee will be performed using several bed positions acquisition, each bed is approximately 15cm axial filed with 4mm special resolution. The time of acquisition of the emission scan is about 2 min for each bed, with a total time range between 12 and 17 min.
- interventionNames
- Other: PET/CT technique
Primary outcomes (1)
- measure
- Sensitivity of fluoro-2- deoxy-D-glucose (FDG) Positron emission tomography (PET) /computed tomography (CT) to predict hepatocellular carcinoma (HCC)
- timeFrame
- From 1 month to 3 months post radiofrequency ablation
- description
- Sensitivity of fluoro-2- deoxy-D-glucose (FDG) Positron emission tomography (PET) /computed tomography (CT) to predict hepatocellular carcinoma (HCC) will be measured.
Secondary outcomes (3)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 40 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Age from 40 to 75 years. * Both sexes. * Patients with hepatocellular carcinoma (HCC) and underwent radiofrequency ablation (RFA) . Exclusion Criteria: * Patients with past history of contrast allergy. * Patients with blood glucose level \>200 mg/dl at the time of the study. * High serum creatinine\> 2 mg / dl. * Small lesions \< 10 mm. * Well differentiated hepatocellular carcinoma (HCC) lesions by pathology.
References
Publications (0)
Data not yet available
No reference posted for this study.